We are live on ! Find out more
AI

Alphabet Inc Portfolio holdings

AUM $4.02B
1-Year Est. Return 215.74%
This Fund
S&P 500
This Quarter Est. Return
+30.24%
1 Year Est. Return
+215.74%
3 Year Est. Return
+350.01%
5 Year Est. Return
+242.03%
10 Year Est. Return
+998.87%
AUM
$2.16B
AUM Growth
+$600M
Cap. Flow
+$129M
Cap. Flow %
6%
Top 10 Hldgs %
88.29%
Holding
46
New
1
Increased
4
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$309M
2
RVMD icon
Revolution Medicines
RVMD
+$127M
3
VERV
Verve Therapeutics
VERV
+$22.3M
4
NMRA icon
Neumora Therapeutics
NMRA
+$2.52M
5
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$6

Top Sells

Rank Stock Value
1
PATH icon
UiPath
PATH
+$137M
2
EQRX
EQRx, Inc. Common Stock
EQRX
+$106M
3
OSCR icon
Oscar Health
OSCR
+$88.7M
4
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
+$208K

Sector Composition

Rank Sector Weight
1 Healthcare 48.63%
2 Technology 47.2%
3 Industrials 4.04%
4 Consumer Staples 0.12%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
26
Autolus Therapeutics
AUTL
$389M
$4.5M 0.21%
698,262
– –
FHTX icon
27
Foghorn Therapeutics
FHTX
$305M
$3.23M 0.15%
500,901
– –
TNYA icon
28
Tenaya Therapeutics
TNYA
$167M
$2.97M 0.14%
915,705
– –
BHIL
29
DELISTED
Benson Hill, Inc.
BHIL
$2.61M 0.12%
438,636
– –
DNTH icon
30
Dianthus Therapeutics
DNTH
$5.71B
$2.17M 0.1%
208,697
– –
KRON
31
DELISTED
Kronos Bio
KRON
$1.8M 0.08%
1,438,232
– –
EXAS
32
DELISTED
Exact Sciences
EXAS
$1.72M 0.08%
23,205
– –
RANI icon
33
Rani Therapeutics
RANI
$91M
$1.49M 0.07%
448,492
– –
ALEC icon
34
Alector
ALEC
$168M
$1.4M 0.07%
175,866
– –
SPRO icon
35
Spero Therapeutics
SPRO
$68.3M
$1.31M 0.06%
889,979
– –
TSHA icon
36
Taysha Gene Therapies
TSHA
$1.59B
$1.13M 0.05%
640,882
– –
HYPR icon
37
Hyperfine
HYPR
$95.3M
$1.01M 0.05%
898,720
– –
SNCE
38
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$856K 0.04%
160,364
+1
+0% +$6
QNCX icon
39
Quince Therapeutics
QNCX
$17.5M
$199K 0.01%
946
– –
NVTA
40
DELISTED
Invitae Corporation
NVTA
$148K 0.01%
235,606
– –
FULC icon
41
Fulcrum Therapeutics
FULC
$249M
$96.3K ﹤0.01%
14,262
– –
RGEN icon
42
Repligen
RGEN
$7.39B
$68.9K ﹤0.01%
383
– –
MOND
43
DELISTED
Mondee Holdings, Inc. Class A Common Stock
MOND
$50.8K ﹤0.01%
18,420
– –
HLTH
44
DELISTED
Cue Health Inc. Common Stock
HLTH
$4.32K ﹤0.01%
27,000
– –
EQRX
45
DELISTED
EQRx, Inc. Common Stock
EQRX
– –
-47,675,476
Closed -$106M
EVLO
46
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
– –
-53,024
Closed -$208K
1
2

Similar funds

JSW
Journey Strategic Wealth Summit, New Jersey $4.03B AUM 33.12% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.04B AUM 1.15% 1-Year Est. Return
MAM
Martingale Asset Management Boston, Massachusetts $3.99B AUM 22.65% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return
ICP
Ilex Capital Partners London, United Kingdom $4.06B AUM 6.11% 1-Year Est. Return
CA
CSM Advisors Warrendale, Pennsylvania $4.07B AUM 29.62% 1-Year Est. Return
MGP
Metis Global Partners San Diego, California $4.07B AUM 30.82% 1-Year Est. Return

Alphabet Inc's Q4 2023 Portfolio in Review

As of Q4 2023, Alphabet Inc held 46 positions worth $2.16B, up 39% from $1.56B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Alphabet Inc deployed $129M of net new capital in Q4 2023, opening 1 new position and adding to 4 existing holdings. Its largest new stake was Revolution Medicines: 5,301,512 shares worth $152M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 39% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was UiPath, an estimated $137M trimmed.

  • Alphabet Inc's largest Q4 2023 buy was Revolution Medicines: 5,301,512 shares worth $152M.
  • Alphabet Inc added most to DexCom in Q4 2023, an estimated $309M increase.
  • Alphabet Inc's biggest Q4 2023 reduction was UiPath, cutting an estimated $137M.
  • Alphabet Inc fully exited EQRx, Inc. Common Stock in Q4 2023, selling an estimated $106M.
  • Alphabet Inc's ten largest holdings make up 88% of its $2.16B portfolio in Q4 2023.
  • Alphabet Inc opened 1 new position and closed 2 in Q4 2023.
  • Alphabet Inc's portfolio value rose 39% quarter-over-quarter to $2.16B.

Based on Alphabet Inc's 13F filing for Q4 2023, filed 9 Feb 2024.